PHAR (Pharming Group) Quality Rank


PHAR Pharming Group PHAR
77 GF Score
Price $13.72
GF Value $14.50
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Pharming Group Quality Rank Related Terms

PHAR
77GF Score
Pharming Group PHAR
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.72 is trading 5.4% below its estimated GF Value™ of $14.50. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Quality Rank:
  • GF Value™: $14.50 vs. price of $13.72 (5.4% below fair value)
  • GF Score™: 77/100 with 1 warning sign

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
77GF Score

Get the complete analysis for PHAR

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.72
Price
$14.50
GF Value